Thomas V. O'Halloran is CEO & CSO +2 at Monopar Therapeutics (MNPR). They have made 1 open-market trade across 1 company since 2019, most recently 2019-12-18.
CIK 0001727481
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.0M since 2019, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MNPR | 291,667 | $20.3M |
Shares reported on the most recent Form 4, priced at the 2019-12-20 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MNPR | BUY | 2019-12-18 | 2019-12-20 | $8.00 | $1.0M | -31.5% | -31.7% | -73.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.